Get Help Now

Contact a Lawyer in
North or South Carolina.


A class of diabetes medications called SGLT2 inhibitors impede the reabsorption of glucose in the kidneys, helping patients with Type 2 diabetes lower their blood sugar. Unfortunately, these medications—including Invokana®, Invokamet®, and Farxiga®—are associated with severe side effects and complications.

The U.S. Food and Drug Administration (FDA) released a Drug Safety Communication in May 2017 confirming that the drugs are associated with an increased risk of leg and foot amputations. The FDA also reported in May 2015 that patients who take SGLT2 inhibitors may develop ketoacidosis, which is a potentially fatal acid build-up that occurs when there’s a lack of insulin in the body.

If you or a loved one took Invokana, Invokamet, or Farxiga and developed ketoacidosis or required amputation of your foot or leg, you may be eligible to pursue a claim for compensation. The drug injury attorneys at Crumley Roberts can investigate your medication-related complications and help protect your rights. Call us at (866) 336-4547 or complete a free online form.

FDA Reports Invokana®, Invokamet® Amputation Risk

In May 2017, the FDA reviewed data from two large clinical trials that indicated the medication canagliflozin—also known as Invokana, Invokamet, and Invokamet XR—resulted in an increased risk of leg and foot amputations.

The clinical trials revealed that patients taking canagliflozin were most likely to experience amputations of the toe and middle of the foot, but some required amputations below and above the knee. Other patients even required amputation of parts of both legs.

In response, the FDA required that the drug’s manufacturers add Boxed Warnings—the most prominent warning for drugs—to the packaging and labels of the medications.

SGLT2 Inhibitors Can Cause Ketoacidosis

In May 2015, the FDA reviewed 73 cases where Type 1 or Type 2 diabetes patients taking SGLT2 inhibitors developed ketoacidosis. This condition causes symptoms that include:

  • Nausea
  • Vomiting
  • Abdominal pain
  • Tiredness
  • Trouble breathing

Some patients also developed life-threatening blood infections, as well as urinary tract infections that progressed to kidney infections. All the patients who suffered these complications were hospitalized, with some needing treatment in intensive care units or dialysis to treat kidney failure.

In response, the FDA required that all SGLT2 inhibitor medications include warnings on their labels about the risk of ketoacidosis and urinary tract infections.

Which Drugs are Linked to Ketoacidosis?

There are several SGLT2 inhibitor medications that are manufactured by different pharmaceutical companies under various brand names, such as:

  • Invokana® (canagliflozin)
  • Invokamet® and Invokamet XR® (canagliflozin and metformin)
  • Farxiga® (dapagliflozin)
  • Xigduo XR® (dapagliflozin and metformin extended-release)
  • Jardiance® (empagliflozin)
  • Glyxambi® (empagliflozin and linagliptin)

The FDA recommends that patients who experience symptoms of ketoacidosis after taking any of these drugs seek medical attention immediately.

Other Side Effects Associated with SGLT2 Inhibitors

Complications associated with drugs like Invokana, Invokamet, and Farxiga aren’t limited to amputations and ketoacidosis.

Patients who take these drugs also may be at an increased risk for:

  • Elevated potassium levels
  • Low blood sugar levels
  • Coma
  • Kidney failure
  • Fluid buildup in the brain
  • Low blood pressure
  • Stroke

Maximize Your Chances of Getting Compensation

SGLT2 inhibitor-related side effects and complications can be devastating. At Crumley Roberts, we believe that innocent victims like you deserve maximum compensation.

If you or a loved one was hospitalized, developed ketoacidosis, or required amputation after taking a Type 2 diabetes drug, we can protect your rights to the money you deserve. Dial (866) 336-4547 or submit an online contact form today.

Invokana® and Invokamet® are registered trademarks of Janssen Pharmaceuticals, Inc., and are used here only to identify the products in question. Farxiga® and Xigduo XR® are registered trademarks of Astrazeneca, plc, and are used here only to identify the product in question. Jardiance® and Glyxambi® are registered trademarks of Boehringer Ingelheim Pharmaceuticals, Inc., and are used here only to identify the product in question.

This law firm is not associated with, sponsored by, or affiliated with AstraZeneca plc; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceticals, Inc.; or the U.S. Food and Drug Administration.

Free Initial Consultation